Biomarker predicts effectiveness of brain cancer temozolomide treatment

Biomarker predicts effectiveness of brain cancer treatment – Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma – the most common form of primary brain cancer – will respond to chemotherapy.

Bevacizumab offers no benefit for glioblastoma

Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds – Avastin – bevacizumab failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting.

Brain cancer vaccine prepared from brain tumor proves effective

Brain cancer vaccine proves effective — With help of patient groups, phase 2 clinical trial paves way for testing therapy that combines cancer vaccine with the drug Avastin – A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

Avastin bevacizumab approval revoked to treat breast cancer in US

Avastin Loses FDA Approval to Treat Breast Cancer – US health agency FDA Commissioner Margaret A. Hamburg, M.D. has revoked the approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use.

Avastin approved for brain cancer Glioblastoma

FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy. – Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with glioblastoma with progressive disease following prior therapy.

Brain cancer malignant glioma linked to gene mutations

Newly discovered gene could be a prime target in the most lethal brain cancer – Scientists at Duke University Medical Center and Johns Hopkins University have discovered mutations in two genes that could become therapeutic targets in malignant glioma, a dangerous class of brain tumors.

Brain cancer glioblastoma study possible with mouse model

Salk researchers develop novel brain cancer glioblastoma mouse model. – Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally.

New genes identified linked to lung cancer

Scientists find new genes linked to lung cancer. Discovery opens door to individualized treatment strategies. – Working as part of a multi-institutional collaboration, scientists at Washington University School of Medicine in St. Louis have assembled the most complete catalog to date of the genetic changes underlying the most common form of lung cancer.

Family history of brain tumors raises brain cancer risk

Researchers revealed that having a family history of cancerous brain tumors puts you at a higher risk of developing the same kind of brain tumor. – People with a family history of cancerous brain tumors appear to be at higher risk of developing the same kind of tumors compared to people with no such family history, according to a study published in the September 23, 2008, issue of Neurology?, the medical journal of the American Academy of Neurology.

Vitamin C injections slow tumor growth

High-dose injections of vitamin C may reduce tumor weight and growth rate by about 50 percent of brain, ovarian, and pancreatic cancers, – High-dose injections of vitamin C, also known as ascorbate or ascorbic acid, reduced tumor weight and growth rate by about 50 percent in mouse models of brain, ovarian, and pancreatic cancers, researchers from the National Institutes of Health (NIH) report in the August 5, 2008, issue of the Proceedings of the National Academy of Sciences.